Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Ophthalmology
Published in: BMC Ophthalmology 1/2018

Open Access 01-12-2018 | Research article

Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)

Authors: Zijing Li, Yichi Zhang, Yunru Liao, Rui Zeng, Peng Zeng, Yuqing Lan

Published in: BMC Ophthalmology | Issue 1/2018

Login to get access

Abstract

Background

Retinopathy of Prematurity (ROP) is one of the most common causes of childhood blindness worldwide. Comparisons of anti-VEGF and laser treatments in ROP are relatively lacking, and the data are scattered and limited. The objective of this meta-analysis is to compare the efficacy of both treatments in type-1 and threshold ROP.

Methods

A comprehensive literature search on ROP treatment was conducted using PubMed and Embase up to March 2017 in all languages. Major evaluation indexes were extracted from the included studies by two authors. The fixed-effects and random-effects models were used to measure the pooled estimates. The test of heterogeneity was performed using the Q statistic.

Results

Ten studies were included in this meta-analysis. Retreatment incidence was significantly increased for anti-VEGF (OR 2.52; 95% CI 1.37 to 4.66; P = 0.003) compared to the laser treatment, while the incidences of eye complications (OR 0.29; 95% CI 0.10 to 0.82; P = 0.02) and myopia were significantly decreased with anti-VEGF compared to the laser treatment. However, there was no difference in the recurrence incidence (OR 1.86; 95% CI 0.37 to 9.40; P = 0.45) and time between treatment and retreatment (WMD 7.54 weeks; 95% CI 2.00 to 17.08; P = 0.12).

Conclusion

This meta-analysis indicates that laser treatment may be more efficacious than anti-VEGF treatment. However, the results of this meta-analysis also suggest that laser treatment may cause more eye complications and increase myopia. Large-scale prospective RCTs should be performed to assess the efficacy and safety of anti-VEGF versus laser treatment in the future.
Appendix
Available only for authorised users
Literature
1.
Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77–82.CrossRefPubMed
2.
Early Treatment For Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94.CrossRef
3.
JA MN, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology. 1991;98:576–80.CrossRef
4.
Brooks SE, Johnson M, Wallace DK, Paysse EA, Coats DK, Marcus DM. Treatment outcome in fellow eyes after laser photocoagulation for retinopathy of prematurity. Am J Ophthalmol. 1999;127:56–61.CrossRefPubMed
5.
Banach MJ, Ferrone PJ, Trese MT. A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology. 2000;107:324–7. discussion 328CrossRefPubMed
6.
Banach MJ, Berinstein DM. Laser therapy for retinopathy of prematurity. Curr Opin Ophthalmol. 2001;12:164–70.CrossRefPubMed
7.
Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2017;101(3):365–70.PubMed
8.
Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS. 2015;19:140–4.CrossRefPubMed
9.
Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after Intravitreal Bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008–15.CrossRefPubMedPubMedCentral
10.
Yoon JM, Shin DH, Kim SJ, Ham DI, Kang SW, Chang YS, et al. Outcomes after laser versus combined laser and Bevacizumab treatment for type 1 retinopathy of prematurity in zone I. Retina. 2017;37(1):88–96.CrossRefPubMed
11.
Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of Bevacizumab, Ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462–9.
12.
Moran S, O'Keefe M, Hartnett C, Lanigan B, Murphy J, Donoghue V. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta Ophthalmol. 2014;92:e496–7.CrossRefPubMed
13.
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.CrossRefPubMedPubMedCentral
14.
Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina. 2008;28:839–46.CrossRefPubMed
15.
Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Lond). 2014;28:1080–6. quiz 1087CrossRef
16.
Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155:1119–24. e1111CrossRefPubMed
17.
Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS. 2012;16:2–4.CrossRefPubMed
18.
dell ’Omo R, Kulkarni A, Franks WA. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity. Acta Ophthalmol. 2008;86:698–700.CrossRef
19.
Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology. 2011;118:176–83.CrossRefPubMed
20.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3:e123–30.PubMedPubMedCentral
21.
Petrisor BA, Keating J, Schemitsch E. Grading the evidence: levels of evidence and grades of recommendation. Injury. 2006;37(4):321–7.CrossRefPubMed
22.
Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration,
23.
Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.CrossRefPubMedPubMedCentral
24.
Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity. Ophthalmology. 2014;121:2212–9.CrossRefPubMed
25.
Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M, et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 2016;94(6):e417–20.CrossRefPubMed
26.
Walz JM, Bemme S, Pielen A, Aisenbrey S, Breuss H, Alex AF, et al. The German ROP registry: data from 90 infants treated for retinopathy of prematurity. Acta Ophthalmol. 2016;94(8):e744–e752.CrossRefPubMed
27.
Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical Management of Recurrent Retinopathy of prematurity after Intravitreal Bevacizumab Monotherapy. Ophthalmology. 2016;123(9):1845–55.CrossRefPubMedPubMedCentral
28.
Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal Fluorescein angiographic study. Retina. 2017;37(1):97–111.CrossRefPubMed
29.
Xiang N, Zhao MJ, Li XY, Zheng HH, Li GG, Li B. Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro. Ophthalmic Res. 2011;45:92–101.CrossRefPubMed
30.
Kuo HK, Sun IT, Chung MY, Chen YH. Refractive error in patients with retinopathy of prematurity after laser photocoagulation or Bevacizumab Monotherapy. Ophthalmologica. 2015;234:211–7.CrossRefPubMed
31.
Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev. 2012;88:937–41.CrossRefPubMed
32.
Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000–6.CrossRefPubMed
33.
Hurley BR, JA MN, Fineman MS, Ho AC, Tasman W, Kaiser RS, et al. Laser treatment for retinopathy of prematurity: evolution in treatment technique over 15 years. Retina. 2006;26:S16–7.CrossRefPubMed
34.
35.
Nguyen PH, Catt C, Nguyen TX, Pham VT. Refractive outcome of prethreshold retinopathy of prematurity treated by diode laser: follow-up at 5 years. Clin Ophthalmol. 2015;9:1753–8.CrossRefPubMedPubMedCentral
36.
37.
Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327–33.CrossRefPubMed
38.
Yi Z, Su Y, Zhou Y, Zheng H, Ye M, Xu Y, et al. Effects of Intravitreal Ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res. 2016;41(8):1092–7.CrossRefPubMed
39.
EM ML, O'Keefe M, SF ML, Lanigan BM. Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity. J AAPOS. 2006;10:454–9.CrossRef
40.
Quinn GE, Dobson V, Repka MX, Reynolds J, Kivlin J, Davis B, et al. Development of myopia in infants with birth weights less than 1251 grams. The Cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology. 1992;99:329–40.CrossRefPubMed
41.
Connolly BP, Ng EY, JA MN, Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology. 2002;109:936–41.CrossRefPubMed
42.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–9.CrossRefPubMed
43.
McLoone E, O’Keefe M, McLoone S, Lanigan B. Effect Of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus. 2007;44:170–3.PubMed
44.
Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013;33:329–38.CrossRefPubMed
45.
Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and Bevacizumab treatment. PLoS One. 2016;11:e0148019.CrossRefPubMedPubMedCentral
46.
Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following Bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137(4):e20153218.CrossRefPubMed
47.
Gotz-Wieckowska A, Kociecki J, Burchardt-Kroll E, Gadzinowski J. The results of diode treatment of active phase of retinopathy of prematurity. Klin Ocz. 2003;105:395–7.
48.
Erol MK, Coban DT, Sari ES, Bilgin AB, Dogan B, Ozdemir O, et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:340–3.PubMed
49.
Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2015;35:667–74.CrossRefPubMed
Metadata
Title
Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)
Authors
Zijing Li
Yichi Zhang
Yunru Liao
Rui Zeng
Peng Zeng
Yuqing Lan
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2018
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-018-0685-6

Other articles of this Issue 1/2018

BMC Ophthalmology 1/2018 Go to the issue

Research article

Outcomes of complex Descemet Stripping Endothelial Keratoplasty performed by cornea fellows

Research article

Risk factors of presenile nuclear cataract in health screening study

Research article

Metabolic characterization of human aqueous humor in the cataract progression after pars plana vitrectomy

Case report

Management of Giant Retinal Tear with microincision vitrectomy and metallic retinal tacks fixation-a case report

Case report

Decompression retinopathy following nonpenetrating deep sclerectomy for primary congenital glaucoma

Research article

Comparing safety and efficiency of two closed-chamber techniques for iridodialysis repair - a retrospective clinical study